User: Guest

GENETIC TESTING

Global Market Trajectory & Analytics

MCP-1392

VALIDATED EXECUTIVE ENGAGEMENTS

POOL + OUTREACH

11296
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

1356
Interactions with Platform & by Email

PARTICIPANTS

339
Unique # Participated

VALIDATIONS

153
Responses Validated*
* Login to view program details and full enterprise executive list.

DATE

OCTOBER 2020

TABLES

108

PAGES

573

EDITION

17

PRICE

USD $5600


The global market for Genetic Testing is forecast to reach US$18.9 billion by the year 2027, trailing a post COVID-19 CAGR of 8.6% over the analysis period 2020 through 2027. While deaths due to communicable diseases are expected to decline, mortality rates of non-communicable diseases is forecast to rise significantly. Non-communicable diseases like cardiovascular diseases and cancer represent the leading cause of death, disability and rising healthcare costs worldwide. Predictive genetic testing has the potential to play a key role in fighting this challenge by identifying genetic changes or mutations linked to diseases before onset of symptoms. This helps in effective management of disease progression and mortality by influencing modifiable risk factors and increasing chances of disease prevention. Conventional physician-initiated genetic testing models are intended for individuals with or at the risk of specific medical conditions. Healthcare professionals decide about these tests and order clinical-grade tests from recognized labs. The approach represents the most popular delivery model for genetic testing. The market also encompasses Direct-to-Consumer (DTC) or the consumer-initiated testing model that doesn't involve a healthcare provider. Hybrid DTC is another model that involves patient-initiated testing along with the participation of medical professional.


Companies offering these tests allow consumers to order tests online while closely working with a genetic counselor or physician network for safeguarding ordering as well as delivery of test results. Another model involves delivery of the elective genetic analysis to people through executive health and wellness clinics. Genetic sequencing relies on three approaches including whole-genome sequencing (WGS), targeted panels and whole-exome sequencing (WES). WGS focuses on reading the complete genome that covers more than 3.3 billion DNA base pairs to understand genome and the role on non-coding regions in influencing disease phenotype and gene expression. However, the method increases turnaround time, is expensive and complicates the data analysis process. In addition, the unavailability of reimbursement has limited the use of WGS for research. On the other hand, approaches to reduce analytical complexity are likely to drive its adoption for clinical use for informed treatment and prognosis. WES sequences the protein-coding exome, and offers a faster and less expensive option and offers deeper sequencing for better accuracy than WGS. The technique holds limited reimbursement for diagnosis of non-specific genetic conditions. WES is a popular approach for complex clinical diagnostics and selection of suitable treatment.


Cancer has emerged as one of the most critical health issues faced by the medical world. As per the National Cancer Institute (NCI), more than 13 million people are diagnosed with cancer each year, with relatively higher incidences noted among men. In the developed as well as the developing countries across the world, cancer is the leading cause of mortality, with the proportion comparatively higher in the developing countries. Major cancers, associated with such chronic infectious conditions as cervix and stomach, have become less common with the economic development of several countries. There is a significant rise in the number of individuals affected by rare cancer conditions such as renal cell carcinoma, GBM, lysosomal storage disorders and acute myeloid leukemia among various other orphan indications of cancer in both developed as well as developing countries. The market for breast cancer gene testing is on the rise, given its preventative aspect against the disease. Each year, in the US, about 250,000 women are newly diagnosed with breast cancer, of which about 10% cases occur due to a hereditary, identifiable gene mutation. Common mutations include those in BRCA½ genes, attributed to 16% of all hereditary breast cancers. Incidence of familial breast cancer is increasing considerably in specific ethnic groups including the Ashkenazi Jews. Predictive gene tests, for instance BRACAnalysis test from Myriad Genetics, identify women at risk. Clinically, the test is suggested for high-risk women with breast cancer in their family circles and women already diagnosed with breast cancer, to determine tumor biology. Apart from the U.S. and Europe, densely populated developing countries such as China harbor the largest potential for breast cancer gene testing market.

23andMe Inc.; Abbott Laboratories; AutoGenomics Inc.; Biocartis NV; BioRad Laboratories; Cepheid Inc.; ELITech Group S.P.A.; Illumina Inc.; Laboratory Corporation of America Holdings; Luminex Corporation; Natera Inc.; PerkinElmer Inc.; QIAGEN N.V.; Quest Diagnostics Inc.; Roche Diagnostics AG.; Roche Molecular Diagnostics Inc.; Sequenom Inc.; Thermo Fischer Scientific Inc.
» Type (Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic, Other Types) » Application (Cancer, Genetic Disease, Cardiovascular Disease, Other Applications)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

ACTIVE CLIENT

INACTIVE CLIENT

ACTIVE PANELIST

INACTIVE PANELIST

OPT-INS

FEATURED COMPANIES

Registration is required to access our data stacks.

WORLD BRANDS

Registration is required to access our data stacks.

EXECUTIVES ENGAGED

Registration is required to access our data stacks.

KEY DIFFERENTIATORS

We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.

* A review of 262 off-the-shelf market report publishers worldwide.

WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.

Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.

Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)

A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.

Where relevent and possible we present competitive brands.

Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.

Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.

Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.

We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.

  
05
1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
A Prelude to Genetic Testing
Top Ten Genetic Diseases Worldwide
Different Types of Genetic Tests include
Prenatal and Newborn Screening
Diagnostic Testing
Predictive & Presymptomatic Testing
Carrier Identification
Pharmacogenomic Testing
List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
Genetic Testing Delivery Models
Genetic Sequencing Approaches
Genetic Testing Market Witnesses Sluggish Growth during COVID-19, Set to Record Exponential Growth Post-COVID
Expanding Applications to Drive Genetic Testing Market
Regional Landscape
Prenatal Testing Market to Rise
Market Outlook
2. FOCUS ON SELECT PLAYERS
Recent Market Activity
World Brands
Innovations
3. MARKET TRENDS & DRIVERS
Studies Indicate Possible Correlation between Genetic Variations Tied to Immunity and COVID-19 Severity
SEGMENT ANALYSIS
Prenatal Testing Changing the World of Pregnancy Care
List of Available Prenatal Screening and Diagnostic Tests by Indication
Players in the Prenatal and New Born Genetic Testing Market
Conventional Invasive Pre-Natal Diagnostic Techniques A Risky Affair
Emergence of Non-Invasive Prenatal Diagnosis (NIPD)
Competition Intensifies in the NIPD Market
Strain on Resources Prevent Wide Adoption of Expanded Carrier Sequencing
Predictive Diagnostics
Breast Cancer Gene Testing Market to Expand Strongly
Myriad Genetics A Leader in Breast Cancer Testing
Discovery of Novel Biomarkers Crucial to Predictive Diagnostics
Pharmacogenomics Development Augurs Growth of Genetic Testing Market
MARKET TRENDS AND GROWTH DRIVERS
Genetic Testing Paves the Way for Personalized Medicine
TABLE 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medic
Next-Generation Sequencing (NGS) A Giant Leap in Genome Sequencing
Biomarker Discovery Leads to Advanced Genetic Testing
Select List of Available Tumor Markers
Immense Popularity of Ancestry Testing
Increasing Focus on Data Churning
Genetic Testing to Explode into Provider Workflow with Intriguing Use Cases
Primary Factors Responsible for Waning Interest in Direct-to Consumer Genetic Testing
Liquid Biopsy to Facilitate Cancer Diagnosis and Treatment
Hybrid Labs to Bridge Gap Between Traditional and DTC Models
Rising Prevalence of Cancer and Chromosomal Disorders Augments Demand for Cell-Free DNA Testing
Emergence of Rapid DNA Testing
Oncology A Key Focus Area for Genetic Testing
EXHIBIT 1: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Ageing Demographics to Drive Demand for Genetic Testing
EXHIBIT 12: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Prenatal & Newborn by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Predictive & Presymptomatic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Carrier by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Pharmacogenomic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Genetic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
GEOGRAPHIC MARKET ANALYSIS
United States
Use of Genomic Data in Clinical Settings to Gather Pace
The United States: Leading Market for Genetic Testing Globally
Predictive Screening: Another Growth Area
Growing Relevance of Personalized Medicine Augurs Well
Rising Incidence of Cancer in the US: Driver for Cancer Genetic Testing
Estimated Number of New Cancer Cases and Deaths in the US (2019)
Newborn Testing Gains Ground
Invasive Prenatal Diagnosis Gives Way to Non-Invasive Prenatal Testing
Coverage of NIPT in Average Risk Pregnancies Expands Target Market
Direct-to-Consumer Testing: A Growing Market
Favorable Reimbursement Policies
Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing
Demographic Changes Offer Growth Opportunities
TABLE 14: North American Aging Population by Age Group: 1975-2050
Skepticism Limits Widespread Adoption of Genetic Testing
Competitive Overview
Myriad Eyes Diversification and Expansion for Growth
Natera Holds Fort in the NIPT Market
Invitae Banks on Low Cost Solutions for Expanding Revenues
Regulatory Environment
Genetic Information Nondiscrimination Act Boosts Genetic Testing
Stricter Regulations for DTC Genetic Testing
FDA Attempts to Put a Leash around Unapproved DTC Genetic Tests
Select Genetic Test Reimbursement Codes
Market Analytics
USA Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
USA Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
USA 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
USA Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
USA 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
Canada
Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand
Number of New Cancer Cases in Canada: 2019
Regulatory Scenario
Market Analytics
Canada Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Canada Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Canada 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Canada Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Canada 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
Japan
Demographics Drive Market Growth
DTC Genetic Testing Regulatory Scenario
Japan Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Japan Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Japan 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Japan Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Japan 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
China
Market Overview
China Attracts Domestic and Foreign Players
Strong Focus on Genomics
Genetic Testing to Reveal Real Talent in Children A New Popular Application
China to Take Lead in Rapidly Growing Asian Genomics Market
Market Analytics
China Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
China Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
China 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
China Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
China Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
China 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
Europe
European Personalized Medicine Market to Exhibit Robust Growth
Aging Population to Drive Demand for Genetic Testing
TABLE 28: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15-64, and 65 & Above
Legislations/Regulatory Policies in Select European Countries
Legislations Governing Genetic Testing in Select European Countries
Rising Cancer Incidence Augurs Well for European Genetic Testing Market
Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
Europe Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
Europe Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Europe 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Europe 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Europe 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
France
France Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
France Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
France 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
France Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
France Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
France 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
Germany
Parliamentary Regulations
Germany Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Germany Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Germany 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Germany Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Germany 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
Italy
Italy Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Italy Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Italy 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Italy Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Italy 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
United Kingdom
Increased Support for Personalized Medicine to Drive Genetic Testing
SMIP for Pharmacogenomic Testing
Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK
Principles for DTC Genetic Testing Laid out by HGC
UK Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
UK Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
UK 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
UK Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
UK 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
Rest of Europe
Rest of Europe Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of Europe 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of Europe 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
Asia-Pacific
Healthcare Spending in Asia-Pacific: On the Rise
India
Australia and New Zealand
Market Analytics
Asia-Pacific Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Asia-Pacific Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Asia-Pacific 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Asia-Pacific Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Asia-Pacific 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
Rest of World
Predictive Screening: Another Growth Area
Market Analytics
Rest of World Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of World Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of World 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of World Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of World 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
Total Companies Profiled : 249

Click here to request a full table of contents and more details on this project.

INSIDER ACCESS TO

 METHODOLOGY  QUESTIONNAIRE  INFLUENCER NETWORK

Registration is required to access our data stacks.

RESEARCH PANEL

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.

  • Complimentary previews of full stack research data for participated
  • Insider access to research programs including engagements and stats from other panelists
  • Unlimited research credits of $1000 per participated project
  • Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
  • Interact with other panelists via our MarketGlassTM Data Exchange Platform*
  • BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*

* Complete details will be shared with panelists upon formal acceptance.

 GLOBAL EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com